0000000000283975

AUTHOR

M Castro

showing 4 related works from this author

I polimorfismi del gene IRGM sono associati al comportamento fistolizzante della malattia di Crohn.

2008

SNPMalattia di Crohn.
researchProduct

Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Ital…

2001

Several reports have indicated that fecal elastase-1 (EL-1) determination is a new, sensitive, and specific noninvasive pancreatic function test; however, very few patients with malabsorption due to small intestine diseases have been included in the previous studies. The aim of the study was to compare the diagnostic accuracy of fecal EL-1 and fecal chymotrypsin (FCT) in distinguishing between pancreatic maldigestion and intestinal malabsorption. Three groups of subjects were studied: group A included 49 patients with known cystic fibrosis (25 males, median age 5 years); group B included 43 subjects with various small intestine diseases (17 males, median age 6 years); and group C included 4…

AdultMaleSettore MED/09 - Medicina InternaAdolescentCystic FibrosisIntestinal giardiasiFecesSensitivityMalabsorption Syndromesspecificity; pancreatic insufficiency; sensitivity; malabsorption syndrome; intestinal giardiasis; cystic fibrosis; steatorrhea; fecal elastase-1: fecal chymotrypsin; celiac diseaseMalabsorption syndromeCeliac diseaseHumansintestinal giardiasisChildPancreatic ElastaseGastroenterologyInfant NewbornInfantPancreatic DiseasesReproducibility of ResultsClinical Enzyme TestsSteatorrheaIntestinal DiseasesCystic fibrosiChild PreschoolSpecificityFecal elastase-1: fecal chymotrypsinDigestionFemalePancreatic insufficiencyDigestive diseases and sciences
researchProduct

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

2019

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product with…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesAdministration OralType 2 diabeteslaw.inventionSettore MED/13 - Endocrinologia0302 clinical medicineGlucosidesRandomized controlled triallaw030212 general & internal medicineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateBenzhydryl CompoundMiddle AgedMetforminMetforminTreatment Outcomediabetes mellitusDrug Therapy CombinationFemalemedicine.drugHumanAdultmedicine.medical_specialtyGlucagon-Like PeptideGlucosideUrology030209 endocrinology & metabolism03 medical and health sciencesPharmacotherapyDouble-Blind MethodWeight Loss.Diabetes mellitusWeight LossInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsBenzhydryl CompoundsGlycated HemoglobinAdvanced and Specialized NursingHypoglycemic Agentbusiness.industrySemaglutidemedicine.diseaseDiscontinuationDiabetes Mellitus Type 2business
researchProduct

Associazione tra i geni identificati sul cromosoma 21q22 ed MHC e la RCU nella popolazione italiana adulta e pediatrica.

2009

Geni associati.RCU
researchProduct